In vivo functional screens reveal KEAP1 loss as a driver of chemoresistance in small cell lung cancer
Science Advances · 2025
DOI: 10.1126/sciadv.adq7084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Lauren Brumage und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, USA. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Drug Resistance, Neoplasm, Kelch-Like ECH-Associated Protein 1, Lung Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Exquisitely chemosensitive initially, small cell lung cancer (SCLC) exhibits dismal outcomes owing to rapid transition to chemoresistance. Elucidating the genetic underpinnings has been challenging owing to limitations with cellular models. As SCLC patient-derived xenograft (PDX) models mimic therapeutic responses, we perform genetic screens in chemosensitive PDX models to identify drivers of chemoresistance. cDNA overexpression screens identify MYC , MYCN , and MYCL , while CRISPR deletion screens identify KEAP1 loss as driving chemoresistance. Deletion of KEAP1 switched a chemosensitive SCLC PDX model to become chemoresistant and resulted in sensitivity to inhibition of glutamine metabolism. Data from the IMpower133 clinical trial revealed ~6% of patients with extensive-stage SCLC exhibit KEAP1 genetic alterations, with activation of a KEAP1/NRF2 transcriptional signature associated with reduced survival upon chemotherapy treatment. While roles for KEAP1/NRF2 have been unappreciated in SCLC, our genetic screens revealed KEAP1 loss as a driver of chemoresistance, while patient genomic analyses demonstrate clinical importance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, USA.
- Molecular and Cellular Biology Program, University of Washington Seattle, Seattle, WA, USA.
- Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
- Genomics and Bioinformatics Shared Resource, Fred Hutchinson Cancer Center, Seattle, WA, USA.
- Genentech, South San Francisco, CA, USA.
- Department of Cell, Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
ORCID-Profile: Lauren Brumage, Scott Best, Daniel S Hippe, Pritha Chanana, Myung Chang Lee, Zhe Ying, Jae Heun Chung, Anna Vigil, Lucas Sullivan, Barzin Nabet, David MacPherson
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Brumage, L., Best, S., Hippe, D. S., Grunblatt, E., Chanana, P., Wu, F., Lee, M. C., Ying, Z., Ibrahim, A., Chung, J. H., Vigil, A., Fatherree, J., Beronja, S., Paddison, P., Sullivan, L., Nabet, B., & MacPherson, D. (2025). In vivo functional screens reveal KEAP1 loss as a driver of chemoresistance in small cell lung cancer. Science Advances. https://doi.org/10.1126/sciadv.adq7084
Vancouver
Brumage L, Best S, Hippe DS, Grunblatt E, Chanana P, Wu F, et al. In vivo functional screens reveal KEAP1 loss as a driver of chemoresistance in small cell lung cancer. Science Advances. 2025. doi:10.1126/sciadv.adq7084
BibTeX
@article{Brumage2025,
author = {Brumage, Lauren and Best, Scott and Hippe, Daniel S and Grunblatt, Eli and Chanana, Pritha and Wu, Feinan and Lee, Myung Chang and Ying, Zhe and Ibrahim, Ali and Chung, Jae Heun and Vigil, Anna and Fatherree, Jackson and Beronja, Slobodan and Paddison, Patrick and Sullivan, Lucas and Nabet, Barzin and MacPherson, David},
title = {In vivo functional screens reveal KEAP1 loss as a driver of chemoresistance in small cell lung cancer},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.adq7084}
}
EUVIMED